3-吡啶甲基三苯基氯化磷盐酸盐 | 34377-83-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-吡啶甲基三苯基氯化磷盐酸盐
• 英文名称: pyridin-3-ylmethyltriphenylphosphonium chloride hydrochloride
• 英文别名: (3-Pyridinemethylene)triphenylphosphonium chloride hydrochloride；3-pyridinylmethyltriphenylphosphonium chloride hydrochloride；triphenyl(3-pyridylmethyl)phosphonium chloride hydrochloride；3-pyridylmethyltriphenylphosphonium chloride hydrochloride；3-Pyridylmethyl-triphenyl phosphonium chloride hydrochloride；triphenyl(pyridin-3-ylmethyl)phosphanium;chloride;hydrochloride
• CAS: 34377-83-8
• 化学式: C₂₄H₂₁NP*ClH*Cl
• 分子量: 426.325
• InChiKey: DSZOIWAUHRGQQD-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  2.0
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  12.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  1-[(4-甲基苯基)磺酰]-1H-吲哚-3-甲醛 、 3-吡啶甲基三苯基氯化磷盐酸盐 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 0.67h， 生成 E-1-[(4-methylphenyl)sulphonyl]-3-(2-(3-pyridyl)ethenyl)indole
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS AND THEIR USE AS MODULATORS OF P38 MAP KINASE
  [FR] COMPOSES PHARMACEUTIQUES

  摘要：

  公开号：

  WO2003087087A3

文献信息

• Compounds
  申请人：Astra Pharmaeuticals Ltd.

  公开号：US05977105A1

  公开（公告）日：1999-11-02

  A compound of formula I, ##STR1## wherein--X represents (CH.sub.2).sub.n O, (CH.sub.2).sub.n S or C.sub.2 alkylene; n represents 1 or 2; Ar.sup.1 represents indanyl, tetrahydronaphthyl, naphthyl or phenyl, which latter two groups may be substituted by one or more substituents selected from chloro, fluoro, OR.sup.1, O(CH.sub.2).sub.m CONR.sup.20 R.sup.21, C(O)R.sup.2, C.sub.1-6 alkyl (optionally substituted by one or more fluorine atoms), pyridyl, thiazinyl, phenyl or C.sub.7-9 alkylphenyl which latter two groups are optionally substituted by one or more substituent selected from halo, nitro, OR.sup.3, C.sub.1-6 alkyl (optionally substituted by one or more fluorine atoms), C(O)R.sup.4, C(O)OR.sup.5, C(O)N(R.sup.6)R.sup.7, CN, CH.sub.2 OR.sup.14, CH.sub.2 NR.sup.15 R.sup.16, N(R.sup.8)R.sup.9, N(R.sup.10)SO.sub.2 R.sup.11, N(R.sup.12)C(O)R.sup.13, OC(O)R.sup.19 and SO.sub.2 NR.sup.17 R.sup.18 ; m represents an integer 1 to 3; R.sup.1, R.sup.2 and R.sup.3 independently represent H, C.sub.1-10 alkyl (optionally substituted by one or more fluorine atoms), C.sub.7-9 alkylphenyl or phenyl, which latter group is optionally substituted by hydroxy; and R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.15, R.sup.16, R.sup.17, R.sup.18, R.sup.19, R.sup.20 and R.sup.21 independently represent H, C.sub.1-6 alkyl (optionally substituted by one or more fluorine atoms) or phenyl; in which any alkyl group present may be interrupted by one or more oxygen atoms; provided that when X represents CH.sub.2 CH.sub.2, Ar.sup.1 may not represent phenyl or phenyl substituted with one or more substituents OR.sup.1, in which R.sup.1 represents C.sub.1-10 alkyl; or a pharmaceutically acceptable derivative thereof, may be used for the treatment of a reversible obstructive airways disease or allergic conditions of the skin, nose and eye.

  一种具有以下结构式I的化合物，其中--X代表(CH₂)ₙO，(CH₂)ₙS或C₂烷基；n代表1或2；Ar¹代表茚基、四氢萘基、萘基或苯基，后两种基团可以被来自氯、氟、OR¹、O(CH₂)ₘCONR²⁰R²¹、C(O)R²、C₁-₆烷基（可选地被一个或多个氟原子取代）、吡啶基、噻唑基、苯基或C₇-₉烷基苯基的一个或多个取代基所取代；后两种基团可以被来自卤素、硝基、OR³、C₁-₆烷基（可选地被一个或多个氟原子取代）、C(O)R⁴、C(O)OR⁵、C(O)N(R⁶)R⁷、CN、CH₂OR¹⁴、CH₂NR¹⁵R¹⁶、N(R⁸)R⁹、N(R¹⁰)SO₂R¹¹、N(R¹²)C(O)R¹³、OC(O)R¹⁹和SO₂NR¹⁷R¹⁸所选取的一个或多个取代基所取代；m代表整数1到3；R¹、R²和R³独立地代表H、C₁-₁₀烷基（可选地被一个或多个氟原子取代）、C₇-₉烷基苯基或苯基，后一基团可选地被羟基取代；R⁴、R⁵、R⁶、R⁷、R⁸、R⁹、R¹⁰、R¹¹、R¹²、R¹³、R¹⁴、R¹⁵、R¹⁶、R¹⁷、R¹⁸、R¹⁹、R²⁰和R²¹独立地代表H、C₁-₆烷基（可选地被一个或多个氟原子取代）或苯基；其中任何存在的烷基基团可以被一个或多个氧原子中断；但是当X代表CH₂CH₂时，Ar¹不能代表苯基或被一个或多个取代基OR¹取代的苯基，其中R¹代表C₁-₁₀烷基；或其药学上可接受的衍生物，可用于治疗可逆性阻塞性气道疾病或皮肤、鼻子和眼睛的过敏症状。
• Pyridine derivatives and pharmaceutical compositions containing them
  申请人：AstraZeneca UK Limited

  公开号：US06143751A1

  公开（公告）日：2000-11-07

  Compounds of the formula (I) wherein X, R.sup.1, R.sup.2, and Ar.sup.1 as defined in the specification. The compounds are useful medicaments, particularly in the treatment of asthma or rhinitis.

  化合物的公式（I），其中X，R.sup.1，R.sup.2和Ar.sup.1如规范中定义的。这些化合物在药物中有用，特别是在治疗哮喘或鼻炎方面。
• Pharmaceutical compounds
  申请人：Frederickson Martyn

  公开号：US20050124620A1

  公开（公告）日：2005-06-09

  Compounds are disclosed of the formula (I): in which U, T, V and W are each a nitrogen atom or carbon atom. When U, T, V or W is a carbon atom, it may be substituted. The compounds are inhibitors of p38 MAP kinase and are useful for treating inflammatory diseases such as arthritis. An example of such a compound is:

  公式（I）的化合物被披露，其中U、T、V和W分别是氮原子或碳原子。当U、T、V或W是碳原子时，它可以被取代。这些化合物是p38 MAP激酶的抑制剂，可用于治疗炎症性疾病，如关节炎。这样的化合物的一个例子是：
• Pyridinyl and imidazolyl derivatives of benzofurans and benzothiophenes
  申请人：THE UPJOHN COMPANY

  公开号：EP0069521A2

  公开（公告）日：1983-01-12

  Compounds of the formula wherein Z, is pyridinyl or imidazolyl; X, is -(CH2)n-, -0-, -S-, -SO-, -SO2. -CH2-O-, -0-CH2-, -CH2-NR3-, -NR3-CH2-. -CHOH- or -CO-; Y, is -O- or -S-; R2 is H. C1-3 alkyl, phenyl or optionally esterified carboxyl; R7 is H, CH2OH, optionally esterified carboxyl, CN, aminomethyl. aminocarbonyl, CHO or a ketone; either Rg and R12 are independently selected from hydrogen, hydroxy, C1-4 alkyl, fluorine, chlorine, bromine and methoxy, or R9 and R12 are attached to adjacent carbon atoms and together are -O-CH2-O-; = represents a single bond (in which case the compound may be in enantiomeric or racemic form) or a double bond; and m and n are 0,1, 2,3 or 4. These compounds can inhibit TXA2 synthetase.

  式中的化合物 其中 Z 是吡啶基或咪唑基； X 是-(CH2)n-、-0-、-S-、-SO-、-SO2.-CH2-O，-0-CH2-，-CH2-NR3-，-NR3-CH2-。-CHOH-或-CO-；Y 是-O-或-S-；R2 是 H、C1-3 烷基、苯基或任选酯化的羧基；R7 是 H、CH2OH、任选酯化的羧基、CN、氨甲基或者 Rg 和 R12 独立选自氢、羟基、C1-4 烷基、氟、氯、溴和甲氧基，或者 R9 和 R12 连接到相邻的碳原子上，并共同为 -O-CH2-O-； = 代表单键（在这种情况下，化合物可能是对映异构体或外消旋体）或双键；m 和 n 分别为 0、1、2、3 或 4。这些化合物可抑制 TXA2 合成酶。
• TRICYCLIC BENZAZEPINE COMPOUNDS
  申请人：MEIJI SEIKA KAISHA LTD.

  公开号：EP0834512A1

  公开（公告）日：1998-04-08

  Tricyclic benzazepine compounds represented by the following formula (I) and pharmacologically acceptable salts thereof are disclosed. These compounds have antiallergic activity and are useful for treatment and prevention of bronchial asthma, eczema, hives, allergic gastrointestinal troubles, allergic rhinitis, allergic conjunctivitis, etc. wherein R represents a hydrogen atom, substituted C1-6 alkyl or a protective group and R1, R2, R3, and R4 represent a hydrogen atom, a hydroxyl group, substituted C1-4 alkyl, substituted C2-12 alkenyl, substituted C1-12 alkoxy, or substituted amino.

  本发明公开了由下式（I）代表的三环苯并氮杂卓化合物及其药理学上可接受的盐类。这些化合物具有抗过敏活性，可用于治疗和预防支气管哮喘、湿疹、荨麻疹、过敏性胃肠道疾病、过敏性鼻炎、过敏性结膜炎等。 其中 R 代表氢原子、取代的 C1-6 烷基或保护基，R1、R2、R3 和 R4 代表氢原子、羟基、取代的 C1-4 烷基、取代的 C2-12 烯基、取代的 C1-12 烷氧基或取代的氨基。